If you've been following development on Eligium, you're probably at least passingly familiar with the name Shanda Games. You'd be more familiar with it in China, since the company also operates a variety of games from other markets, including Aion, MapleStory, and Dungeons & Dragons Online. And after having a record-breaking quarter, the company is moving in the opposite direction of what you might expect from a successful company: It's going private. The requisite stocks were purchased by a single family, so the company moving out of the public market.
All shares will be jointly purchased by a parent company headed by Shanda's CEO, Shanda's COO (the CEO's son), and the company director (the CEO's wife). A $180 million loan was taken out to ensure that the stocks could be traded, with the purchasers buying shares at a higher price to help ensure the transfer. The board of directors has already approved this move, which means that it should go through without a hitch before the first quarter of 2012.
2011年11月23日星期三
2011年7月14日星期四
Obama administration opposes restrictions on abortion, needle exchange in DC
The Obama administration opposes efforts by Congress to restrict funding for needle exchange and abortions for poor women in the District of Columbia.
The administration issued a policy statement Wednesday about a D.C. appropriations bill that’s headed for the House floor. The bill would bar the district from using local taxpayer dollars to fund abortions for poor women. Historically, such funding has been allowed only when Democrats have controlled the White House and both houses of Congress.
The administration says the funding restriction undermines D.C. home rule. It also says Congress should not ban federal funding for needle exchange in the district, noting that such funding is allowed elsewhere if local officials deem the programs effective.
However, Obama did not threaten to veto the spending bill over the D.C. issues.
Copyright 2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
The administration issued a policy statement Wednesday about a D.C. appropriations bill that’s headed for the House floor. The bill would bar the district from using local taxpayer dollars to fund abortions for poor women. Historically, such funding has been allowed only when Democrats have controlled the White House and both houses of Congress.
The administration says the funding restriction undermines D.C. home rule. It also says Congress should not ban federal funding for needle exchange in the district, noting that such funding is allowed elsewhere if local officials deem the programs effective.
However, Obama did not threaten to veto the spending bill over the D.C. issues.
Copyright 2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2011年5月2日星期一
D. Medical Subsidiary, Spring-Set Health Solutions Ltd
D. Medical Industries Ltd. (NASDAQ:DMED)(TASE:DMED) ("D. Medical" or the "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, has announced that the U.S. Food and Drug Administration ("FDA") has granted its subsidiary, Spring-Set Health Solutions Ltd. (formerly "Medx- Set Ltd."), 510(k) clearance to market its Spring™ Universal Infusion Sets (formerly "Lighty DD Infusion Sets") in the United States.
The U.S. insulin pump and disposables market is large and growing. According to the American Diabetes Association, approximately 26 million diabetes patients live in the United States, constituting 8.3% of its population. Of those, experts estimate that 5.4%, or 1.4 million, suffer from Type 1 diabetes and 350,000 currently rely on insulin pump therapy. A recent U.S. Centers for Disease Control and Prevention report estimated that 1 in 3 Americans will have diabetes by 2050 if current trends continue.
The Spring Universal Infusion Set is compatible with most insulin pumps currently available on the market. Going beyond the minimum requirements of subcutaneous drug delivery, the Spring Universal offers best-in-class features such as a hidden, auto-retractable needle, 360° connector, and smallest one-click, all-in-one inserter.
The core of the Spring Universal Infusion Set is the proprietary Detach-Detect mechanism. In the case the base of the infusion set detaches from the user's body, a blocking mechanism is triggered which, in turn, creates an occlusion. This evokes an occlusion alarm in an insulin pump. This unique feature enables exceptional reliability for continuously controlled and monitored insulin delivery, providing additional safety and peace of mind - especially for athletes and the parents of pediatric patients.
While nothing can completely eliminate the intrusive feeling of the needle's insertion in the daily experience of the person with insulin-dependent diabetes, the Spring Universal Infusion Set has a number of incomparable features specifically focused on reducing the sensation of pain and discomfort. The sensation of pain is controlled by a combination of factors - the needle thickness (gauge), needle shape, speed of insertion, vibration, and tissue friction. Clocked at 12 m/sec, the all-in-one Spring Universal Infusion Set is currently the fastest available insertion mechanism. Besides the convenience of not having to pre-cock the trigger mechanism, the two springs (one responsible for the insertion, and the other for auto-retraction of the needle) enable lightning speed and accuracy.
The U.S. insulin pump and disposables market is large and growing. According to the American Diabetes Association, approximately 26 million diabetes patients live in the United States, constituting 8.3% of its population. Of those, experts estimate that 5.4%, or 1.4 million, suffer from Type 1 diabetes and 350,000 currently rely on insulin pump therapy. A recent U.S. Centers for Disease Control and Prevention report estimated that 1 in 3 Americans will have diabetes by 2050 if current trends continue.
The Spring Universal Infusion Set is compatible with most insulin pumps currently available on the market. Going beyond the minimum requirements of subcutaneous drug delivery, the Spring Universal offers best-in-class features such as a hidden, auto-retractable needle, 360° connector, and smallest one-click, all-in-one inserter.
The core of the Spring Universal Infusion Set is the proprietary Detach-Detect mechanism. In the case the base of the infusion set detaches from the user's body, a blocking mechanism is triggered which, in turn, creates an occlusion. This evokes an occlusion alarm in an insulin pump. This unique feature enables exceptional reliability for continuously controlled and monitored insulin delivery, providing additional safety and peace of mind - especially for athletes and the parents of pediatric patients.
While nothing can completely eliminate the intrusive feeling of the needle's insertion in the daily experience of the person with insulin-dependent diabetes, the Spring Universal Infusion Set has a number of incomparable features specifically focused on reducing the sensation of pain and discomfort. The sensation of pain is controlled by a combination of factors - the needle thickness (gauge), needle shape, speed of insertion, vibration, and tissue friction. Clocked at 12 m/sec, the all-in-one Spring Universal Infusion Set is currently the fastest available insertion mechanism. Besides the convenience of not having to pre-cock the trigger mechanism, the two springs (one responsible for the insertion, and the other for auto-retraction of the needle) enable lightning speed and accuracy.
订阅：
博文 (Atom)